Five new tests will be added to the Medicare Benefits Schedule (MBS) for pre-implantation genetic testing (PGT) of embryos

We congratulate the announcement by Minister Hunt that five new tests will be added to the Medicare Benefits Schedule (MBS) for pre-implantation genetic testing (PGT) of embryos for specific genetic or chromosomal variations prior to implantation.

The five new items to be listed on the MBS include an item to test the reproductive couple the purpose of providing an assay for PGT, one surgical item for an embryo biopsy from an at-risk couple, and a further three items for genetic testing of the biopsied embryo(s).
 
The new testing service rebates will be implemented from 1 November 2021 for eligible couples and individuals who are at risk of passing serious genetic conditions onto their child, such as Spinal Muscular Atrophy, cystic fibrosis, muscular dystrophy, fragile X, neurofibromatosis and Huntington disease.
 
Previously, known carriers of genetic variations were only able to access PGT testing if they were able to pay privately. Pre-implantation Genetic Testing (PGT) is a sophisticated scientific technique which enables only chromosomally healthy embryos or those unaffected by a specific disorder to be selected for transfer during an IVF cycle, maximising the chance of a healthy baby.
 
At Virtus Health, we are proud to offer an internationally recognised pre-implantation genetics program. With this new announcement, we are looking forward to being able to help even more individuals achieve their goal of having happy and healthy babies in the future.

For more information, please refer to the Department of Health media release and the MBS fact sheet.